search
Back to results

A Multiple Dose Study of TD-1211 in Healthy Volunteers and Patients With Opioid-Induced Constipation

Primary Purpose

Healthy, Opioid-induced Constipation

Status
Completed
Phase
Phase 1
Locations
United States
Study Type
Interventional
Intervention
TD-1211
TD-1211
TD-1211
TD-1211
TD-1211
TD-1211
TD-1211
TD-1211
TD-1211
Placebo
Sponsored by
Theravance Biopharma
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Healthy focused on measuring Healthy subjects

Eligibility Criteria

18 Years - 65 Years (Adult, Older Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria:

  • Males and females between 18 and 65 years of age, inclusive
  • Healthy subjects and subjects with documented OIC on stable opioid regimen
  • Willingness to stop all laxatives throughout the OIC screening and treatment period

Exclusion Criteria:

  • Any clinically significant finding in healthy subjects
  • Have participated in another clinical trial of an investigational drug 30 days prior to screening
  • History of chronic constipation prior to opioid therapy in OIC subjects
  • Active medical disorders associated with diarrhea or intermittent loose stools in OIC subjects

Sites / Locations

  • Clinical Research Unit
  • Clinical Research Unit
  • Clinical Research Unit

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm 4

Arm 5

Arm 6

Arm 7

Arm 8

Arm 9

Arm 10

Arm Type

Experimental

Experimental

Experimental

Experimental

Experimental

Experimental

Experimental

Experimental

Experimental

Placebo Comparator

Arm Label

TD-1211 dose level 1

TD-1211 dose level 2

TD-1211 dose level 3

TD-1211 dose level 4

TD-1211 OIC dose level 1

TD-1211 OIC dose level 2

TD-1211 OIC dose level 3

TD-1211 OIC dose level 4

TD-1211 OIC dose level 5

Placebo

Arm Description

Ascending doses

Ascending doses

Ascending doses

Ascending doses

Ascending doses

Ascending doses

Ascending doses

Ascending doses

Ascending doses

Ascending doses

Outcomes

Primary Outcome Measures

Safety and tolerability in healthy subjects and activity in subjects with opioid-induced constipation

Secondary Outcome Measures

Evaluation of the multiple dose pharmacokinetics of TD-1211 following oral administration

Full Information

First Posted
December 22, 2009
Last Updated
January 15, 2021
Sponsor
Theravance Biopharma
search

1. Study Identification

Unique Protocol Identification Number
NCT01040637
Brief Title
A Multiple Dose Study of TD-1211 in Healthy Volunteers and Patients With Opioid-Induced Constipation
Official Title
A Phase 1/Phase 2, Randomized, Double-Blind, Multiple Ascending Dose Study to Assess the Safety, Pharmacokinetics, and Effect on Opioid Analgesia of TD-1211 Administered Orally to Healthy Volunteers and to Assess the Safety, Pharmacokinetics, and Effect on Bowel Movements in Subjects With Opioid-Induced Constipation
Study Type
Interventional

2. Study Status

Record Verification Date
January 2021
Overall Recruitment Status
Completed
Study Start Date
January 2010 (undefined)
Primary Completion Date
October 2010 (Actual)
Study Completion Date
October 2010 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Theravance Biopharma

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
The purpose of this study is to evaluate the safety, tolerability and pharmacokinetics of TD-1211 in healthy subjects and activity in subjects with opioid-induced constipation (OIC).

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Healthy, Opioid-induced Constipation
Keywords
Healthy subjects

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 1, Phase 2
Interventional Study Model
Parallel Assignment
Masking
ParticipantInvestigator
Allocation
Randomized
Enrollment
102 (Actual)

8. Arms, Groups, and Interventions

Arm Title
TD-1211 dose level 1
Arm Type
Experimental
Arm Description
Ascending doses
Arm Title
TD-1211 dose level 2
Arm Type
Experimental
Arm Description
Ascending doses
Arm Title
TD-1211 dose level 3
Arm Type
Experimental
Arm Description
Ascending doses
Arm Title
TD-1211 dose level 4
Arm Type
Experimental
Arm Description
Ascending doses
Arm Title
TD-1211 OIC dose level 1
Arm Type
Experimental
Arm Description
Ascending doses
Arm Title
TD-1211 OIC dose level 2
Arm Type
Experimental
Arm Description
Ascending doses
Arm Title
TD-1211 OIC dose level 3
Arm Type
Experimental
Arm Description
Ascending doses
Arm Title
TD-1211 OIC dose level 4
Arm Type
Experimental
Arm Description
Ascending doses
Arm Title
TD-1211 OIC dose level 5
Arm Type
Experimental
Arm Description
Ascending doses
Arm Title
Placebo
Arm Type
Placebo Comparator
Arm Description
Ascending doses
Intervention Type
Drug
Intervention Name(s)
TD-1211
Intervention Description
Dose level 1
Intervention Type
Drug
Intervention Name(s)
TD-1211
Intervention Description
Dose level 2
Intervention Type
Drug
Intervention Name(s)
TD-1211
Intervention Description
Dose level 3
Intervention Type
Drug
Intervention Name(s)
TD-1211
Intervention Description
Dose Level 4
Intervention Type
Drug
Intervention Name(s)
TD-1211
Intervention Description
Ascending doses
Intervention Type
Drug
Intervention Name(s)
TD-1211
Intervention Description
Ascending doses
Intervention Type
Drug
Intervention Name(s)
TD-1211
Intervention Description
Ascending doses
Intervention Type
Drug
Intervention Name(s)
TD-1211
Intervention Description
Ascending doses
Intervention Type
Drug
Intervention Name(s)
TD-1211
Intervention Description
Ascending doses
Intervention Type
Drug
Intervention Name(s)
Placebo
Intervention Description
Ascending doses
Primary Outcome Measure Information:
Title
Safety and tolerability in healthy subjects and activity in subjects with opioid-induced constipation
Time Frame
Daily pre and post dose assessments throughout the duration of the study period
Secondary Outcome Measure Information:
Title
Evaluation of the multiple dose pharmacokinetics of TD-1211 following oral administration
Time Frame
Daily pre and post dose assessments throughout the duration of the study period

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
65 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: Males and females between 18 and 65 years of age, inclusive Healthy subjects and subjects with documented OIC on stable opioid regimen Willingness to stop all laxatives throughout the OIC screening and treatment period Exclusion Criteria: Any clinically significant finding in healthy subjects Have participated in another clinical trial of an investigational drug 30 days prior to screening History of chronic constipation prior to opioid therapy in OIC subjects Active medical disorders associated with diarrhea or intermittent loose stools in OIC subjects
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Medical Monitor
Organizational Affiliation
Theravance Biopharma
Official's Role
Study Director
Facility Information:
Facility Name
Clinical Research Unit
City
Pasadena
State/Province
California
ZIP/Postal Code
91105
Country
United States
Facility Name
Clinical Research Unit
City
San Antonio
State/Province
Texas
ZIP/Postal Code
78209
Country
United States
Facility Name
Clinical Research Unit
City
Salt Lake City
State/Province
Utah
ZIP/Postal Code
84106
Country
United States

12. IPD Sharing Statement

Learn more about this trial

A Multiple Dose Study of TD-1211 in Healthy Volunteers and Patients With Opioid-Induced Constipation

We'll reach out to this number within 24 hrs